Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses March 27, 2026 Read More »
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan March 26, 2026 Read More »
MD Anderson and Phoenix SENOLYTIX announce cross-licensing agreement of CaspaCIDe™ for cell and gene therapies September 5, 2025 Read More »
